REX AI Equity Premium Income ETF vs Bristol-Myers Squibb Co — how do they compare? REX AI Equity Premium Income ETF trades at $37.45, while Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while REX AI Equity Premium Income ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | BMY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $65.89 |
52-Week Low | $32.45 | $42.60 |
Market Cap | — | $129.94B |
Enterprise Value | — | $163.92B |
Dividend Yield | — | 3.96% |
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.42, up 0.21% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock exhibits a high distribution yield strategy, paying weekly dividends, with recent payouts ranging from $0.23 to $0.26. Support and resistance are tightly clustered around $37-$38, indicating potential volatility. Recent news highlights the fund's transition to weekly distributions and questions about sustainability amid AI market dynamics.
The outlook for AIPI hinges on its ability to sustain high yields through its option-writing strategy, though structural risks and NAV erosion concerns persist. Investment opportunity lies in income generation, but risks include dependency on AI sector performance and capped upside. Analyst sentiment is mixed, with some caution over long-term viability.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Trailing returns across standard periods
Latest headlines on both assets
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →